Conflict of interest statement: Competing Interests: Brandy Young-Gqamana is a 
former employee of Amicus Therapeutics. Nastry Brignol, Hui-Hwa Chang, Richie 
Khanna, Rebecca Soska, Sheela A. Sitaraman, Pol Boudes, David J. Lockhart, 
Kenneth J. Valenzano, and Elfrida R. Benjamin are employed by Amicus 
Therapeutics and are shareholders in the company. Maria Fuller was a 
collaborator with Amicus Therapeutics. All other authors were investigators on 
the Phase 2 clinical studies of migalastat HCl. Dominique P. Germain has 
received research funding, consultancy fees, and travel expenses from Genzyme 
and Shire HGT. Roberto Giugliani is a consultant and investigator for Actelion, 
Amicus, BioMarin, Genzyme and Shire HGT. Derralynn A. Hughes is a consultant for 
Amicus, Shire HGT, Genzyme, Actelion, has been on a Speaker's Bureau for Amicus, 
Shire HGT, Genzyme, and Actelion, and has received grants from Amicus, Shire 
HGT, and Genzyme. Atul Mehta has received honoraria, research funding, 
consultancy fees, and travel expenses from Shire HGT, Genzyme, Actelion, 
Protalix, and Amicus. Kathy Nicholls has received travel and research support 
and speaker's honoraria from Amicus, Shire HGT and Genzyme. Amicus Therapeutics 
funded the research and any publication fees. The α-Gal A (Fabrazyme) used in 
this study is a product produced by Genzyme. Maria Fuller is employed by SA 
Pathology, Adelaide. There are no further patents, products in development or 
marketed products to declare. This does not alter the authors' adherence to all 
of the PLOS ONE policies on sharing data and materials.